{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:39:00Z","timestamp":1769629140523,"version":"3.49.0"},"reference-count":11,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.2169\/internalmedicine.2194-18","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:38:22Z","timestamp":1548974302000},"page":"1577-1581","source":"Crossref","is-referenced-by-count":4,"title":["Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma"],"prefix":"10.2169","volume":"58","author":[{"given":"Takenori","family":"Ikoma","sequence":"first","affiliation":[{"name":"Department of Cardiology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Saotome","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Suwa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Naruse","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Ohtani","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Urushida","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Hematology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Internal Medicine 3, Hamamatsu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28: 1122-1128, 2014.","DOI":"10.1038\/leu.2013.313"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Stewart AK. Carfilzomib for the treatment of patients with relapsed and\/or refractory multiple myeloma. Future Oncol 11: 2121-2136, 2015.","DOI":"10.2217\/fon.15.123"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Grandin EW, Ky B, Cornell RF, Carver J, Lenihan DJ. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail 21: 138-144, 2015.","DOI":"10.1016\/j.cardfail.2014.11.008"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Herrmann J, Wohlert C, Saguner AM, et al. Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail 15: 614-623, 2013.","DOI":"10.1093\/eurjhf\/hft034"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98: 1753-1761, 2013.","DOI":"10.3324\/haematol.2013.089334"},{"key":"6","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1186\/1471-2407-14-915","volume":"14","author":"A Chari","year":"2014","unstructured":"6. Chari A, Hajje D. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer 14: 915, 2014.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"7","unstructured":"7. Shah C, Bishnoi R, Jain A, et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma 59: 2257-2569, 2018."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Milan A, Bruno G, Maffei I, et al. Arterial hypertension and multiple myeloma: physiopathology and cardiovascular risk and 'practical' indications in patients receiving carfilzomib. Curr Hypertens Rev, 2018 (Epub ahead of print).","DOI":"10.2174\/1573402114666180611110547"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Atrash S, Tullos A, Panozzo S, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J 5: e272, 2015.","DOI":"10.1038\/bcj.2014.93"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rosenthal A, Luthi J, Belohlavek M, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J 6: e384, 2016.","DOI":"10.1038\/bcj.2015.112"},{"key":"11","unstructured":"11. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35: 893-911, 2017."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/11\/58_2194-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T05:52:20Z","timestamp":1662875540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/11\/58_2194-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2194-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}